LivaNova (NASDAQ:LIVN) Issues FY 2026 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 4.300-4.400 for the period, compared to the consensus EPS estimate of 4.150. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analysts Forecast Growth

LIVN has been the subject of several research reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of LivaNova in a research note on Tuesday. Robert W. Baird cut their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Stifel Nicolaus set a $85.00 target price on shares of LivaNova in a report on Wednesday. Barclays raised their target price on shares of LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a research report on Thursday, May 7th. Finally, Needham & Company LLC boosted their price target on shares of LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $83.50.

LivaNova Stock Performance

NASDAQ LIVN traded down $1.86 during trading on Thursday, reaching $76.28. 380,641 shares of the company’s stock were exchanged, compared to its average volume of 774,852. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11. The business has a 50 day moving average price of $79.54 and a 200-day moving average price of $70.61. The stock has a market capitalization of $4.19 billion, a P/E ratio of 39.12 and a beta of 0.86. LivaNova has a fifty-two week low of $47.13 and a fifty-two week high of $85.76.

LivaNova (NASDAQ:LIVN) last released its quarterly earnings data on Wednesday, August 5th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.18. The company had revenue of $390.59 million during the quarter, compared to analysts’ expectations of $380.34 million. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The business’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the firm posted $1.05 earnings per share. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. Sell-side analysts forecast that LivaNova will post 3.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of LivaNova stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the completion of the transaction, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.35% of the stock is currently owned by company insiders.

Trending Headlines about LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: LivaNova reported second-quarter earnings of $1.26 per share, above the $1.08 analyst consensus and up from $1.05 a year earlier. Revenue rose 10.8% year over year to $390.6 million, exceeding estimates of $380.3 million. Growth in the Cardiopulmonary and Epilepsy businesses helped drive margin improvement. LivaNova Q2 Earnings and Revenues Beat Estimates, 2026 Outlook Raised
• Positive Sentiment: Management raised its fiscal 2026 adjusted EPS outlook to $4.30-$4.40, above the prior consensus estimate of $4.15. Revenue guidance remains approximately $1.5 billion, generally in line with expectations. LivaNova Raises Guidance on Q2 Beats
• Positive Sentiment: Needham raised its price target on LIVN from $81 to $93 and maintained a “buy” rating, indicating confidence that earnings growth and the improved outlook can support additional upside. Analyst Price Target Report
• Negative Sentiment: The share-price pullback may reflect valuation concerns and profit-taking following a recent 52-week high. LivaNova trades at roughly 39 times earnings, so investors may be demanding continued execution and further upward revisions despite the quarterly beat.

Institutional Trading of LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of the stock. State of Wyoming acquired a new stake in LivaNova during the second quarter worth approximately $31,000. EverSource Wealth Advisors LLC increased its stake in shares of LivaNova by 998.4% during the second quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares during the period. Quarry LP bought a new position in shares of LivaNova during the third quarter worth approximately $36,000. UMB Bank n.a. lifted its holdings in LivaNova by 22.6% during the 4th quarter. UMB Bank n.a. now owns 971 shares of the company’s stock worth $60,000 after purchasing an additional 179 shares during the last quarter. Finally, Johnson Financial Group Inc. acquired a new stake in LivaNova during the 3rd quarter worth approximately $63,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.